 |
676047: Full Reagent Kit for the MXFDG Module
Isotec™ has provided customers with the convenience of a kit that will supply all of our customers needs when producing 18FDG. This kit is equipped with the appropriate quantities of Mannose Triflate, Acetonitrile, Ethanol, Eluent solution, Neutralization solution and Sodium Hydroxide for the production of 18FDG. This kit is designed for the MXFDG Synthesis Module. All of which is indicated in the table below. |
Kit Components Not Sold Separately
Product # |
Compound |
Quantity |
| 675628 |
Eluent Solution |
0.6 mL |
| 439134 |
Acetonitrile |
7 ± 0.2 mL |
| M1568 |
Mannose Triflate |
25 ± 2 mg |
| 493546 |
Ethanol, 200 Proof |
5 ± 0.2 mL |
| 675482 |
Neutralization Solution |
6 ± 0.2 mL |
| 674990 |
Sodium Hydroxide 2N ± 1% |
1± 0.05 mL |
| Z192120 |
3 ml B-D Hypodermic Syringe |
N/A |
 |
676055: Full Reagent Kit for the FXFDG Module
Similar to our MXFDG kit, we have a kit that is designed for a FXFDG Synthesis Module. The FXFDG kit contains kryptofix in a 1.5mL vial, a potassium carbonate solution in a 1.5mL vial, acetonitrile in a 5mL vial with a blue cap, and a 15mL plastic container for our sodium hydroxide. |
Kit Components Not Sold Separately
Product # |
Compound |
Quantity |
| 291110 |
Kryptofix®222 |
20 mg |
| M1568 |
Mannose Triflate |
20 mg |
| 675695 |
Potassium Carbonate |
0.5 mL |
| 439134 |
Acetonitrile |
2 mL |
| 319511 |
Sodium Hydroxide 1N |
1 mL |
|
Bundling
ISOTEC™ also offers customers the opportunity to bundle some of our kit products. The Mannose Triflate for our MXFDG kit and FXFDG kit are packaged and shipped separately. Therefore, by purchasing in bulk 10 x 10 ml vial of 25 mg or 20 mg of Mannose Triflate (red cap), customers can save on costs and space! It is storage made easy. |
 |
|
Other Bundling Opportunities
ISOTEC™ offers bundling opportunities for the Kryptofix®222 used in our FXFDG kit. The material is supplied in a small kit with 10 x 10ml vials. This is a small but convenient way to store your Kryptofix®222 in bulk, when not in use. |
 |
|
